The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.
*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...
Sept 12 (Reuters) - Stories on Roche receiving FDA approval for an injectable version of its multiple sclerosis therapy are incorrect and are withdrawn. There will be no replacement story.
The father of one was 31 when he was last seen alive in Kilkenny Dean Roche's car was found crashed into a tree Gardaí are to launch a review of the mysterious case of a man who was aged 31 when ...
Vikings wide receiver Justin Jefferson has 396 catches for 5,958 yards in his NFL career, which means he’s likely to reach the 400-catch and 6,000-yard milestones on Sunday. That would put him in ...
ASX chairman Damian Roche will retire next month after four years as head of the board of the sharemarket operator, a period marked by the failed roll-out of critical settlement and clearing ...
FRANKFURT, Sept 11 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July ...
Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech.
Roche’s new weight loss can­di­date has the ef­fi­ca­cy the Swiss phar­ma was look­ing for. But it al­so comes with a high rate of side ef­fects … ...
Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday. “We’re not alarmed at all ...